Cargando…

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair

BACKGROUND: P38 mitogen activated protein kinase is an intermediary signal transduction factor with context-specific roles in breast cancer. Recent mechanistic studies add to the growing consensus that P38 is a tumour suppressor, and it may represent a novel target for breast cancer treatment. The a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnston, Simon J., Ahmad, Dena, Aleskandarany, Mohammed A., Kurozumi, Sasagu, Nolan, Chris C., Diez-Rodriguez, Maria, Green, Andrew R., Rakha, Emad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199714/ https://www.ncbi.nlm.nih.gov/pubmed/30352570 http://dx.doi.org/10.1186/s12885-018-4924-2

Ejemplares similares

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes
por: Joseph, Chitra, et al.
Publicado: (2018)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis
por: Shiino, Sho, et al.
Publicado: (2022)

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer
por: Joseph, Chitra, et al.
Publicado: (2019)

Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis
por: Shiino, Sho, et al.
Publicado: (2021)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2017)

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
por: Muftah, Abir A., et al.
Publicado: (2017)

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
por: Kurozumi, Sasagu, et al.
Publicado: (2020)

Chemokine (C‐C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma
por: Sonbul, Sultan N, et al.
Publicado: (2017)

MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
por: Craze, Madeleine L, et al.
Publicado: (2018)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

Clinicopathologic and molecular predictors of axillary lymph node metastasis in early-stage breast cancer: a mathematical predictive model
por: Aleskandarany, MA, et al.
Publicado: (2010)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients
por: Ahmad, Narmeen, et al.
Publicado: (2017)

Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment
por: Hanamura, Toru, et al.
Publicado: (2023)

Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment
por: Hanamura, Toru, et al.
Publicado: (2023)

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Machine learning-based prediction of breast cancer growth rate in vivo
por: Bhattarai, Shristi, et al.
Publicado: (2019)

High nuclear MSK1 is associated with longer survival in breast cancer patients
por: Pu, Xuan, et al.
Publicado: (2018)

The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2022)

38th Conference on Nuclear Spectroscopy and Nuclear Structure
Publicado: (1988)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC
por: Griffin, Nicolas I., et al.
Publicado: (2016)

Fibrocystic breast disease with pleomorphic calcifications and segmental distribution: A case report
por: JiueLan, Kuo, et al.
Publicado: (2023)

Cdc14 in good repair
por: Short, Ben
Publicado: (2010)

Evolving DNA repair synthetic lethality targets in cancer
por: Kulkarni, Sanat, et al.
Publicado: (2022)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

Cross-linking can be good
por: Wells, William A.
Publicado: (2001)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s7ut7jbcfgkk330u45bed684cs